Biomarker developer Oxford BioDynamics welcomed news that Mitsubishi Tanabe Pharma America had enrolled the first first patient in a new clinical study.
Chemicals company Synthomer said it had experienced a slower overall trading environment in the third quarter, which it said it expected to continue into the...